Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.3
5.5
Journals
Biomolecules
Special Issues
Cardiovascular Diseases and Biomarkers
share announcement

Cardiovascular Diseases and Biomarkers

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Biomarkers".

Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 5517

Special Issue Editors

Prof. Dr. Attila Tóth

E-Mail Website
Guest Editor
Division of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, 22 Móricz Zsigmond Street, 4032 Debrecen, Hungary
Interests: TRP channels, myocardial contractility; vascular biology; clinical biomarkers in cardiovascular diseases; angiotensin converting enzymes
Special Issues, Collections and Topics in MDPI journals
Dr. Miklós Fagyas

E-Mail Website
Guest Editor
Division of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, 22 Móricz Zsigmond Street, 4032 Debrecen, Hungary
Interests: laboratory medicine; biomarker research; regulation of the renin-angiotensin-aldosterone system; sarcoidosis

Special Issue Information

Dear Colleagues,

Cardiac biomarkers can make life easier for both clinicians and patients: they are important in diagnosing cardiovascular diseases and monitoring drug or device therapy, and they provide the key to the success of personalized treatment in the 21st century. The rising incidence of cardiovascular diseases, novel drug and invasive therapies in cardiovascular patients, and the aging population all call for the discovery and application of new cardiovascular biomarkers.

We are pleased to invite you to share your latest biomarker research on cardiovascular diseases or to summarize the latest scientific knowledge on novel cardiac biomarker candidates. The aim of this Special Issue is (1) to present novel cardiovascular biomarkers which can be determined by a simple blood or urine test, (2) to outline novel applications of conventional biomarkers in everyday use, and (3) to highlight the potential risks and challenges related to biomarkers used today in the healthcare system.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • New biomarkers for the diagnosis and treatment of cardiovascular diseases and their complications;
  • Cardiovascular biomarkers of the future having a chance to be incorporated into clinical treatment guidelines;
  • Biomarkers to help to improve the effectiveness of drug therapy for cardiovascular patients;
  • Old, conventional cardiovascular biomarkers in a new role;
  • Biomarkers of cardiovascular symptoms and complications in COVID-19;
  • Cardiovascular biomarkers for more accurate risk stratification (preventive medicine);
  • Misuse and misinterpretation of cardiovascular biomarkers: potential risks and possible negative effects;
  • Pre-, post-, and analytical considerations for commonly used cardiovascular biomarkers.

We look forward to receiving your contributions.

Prof. Dr. Attila Tóth
Dr. Miklós Fagyas
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular biomarker
  • personalized medicine
  • cardiovascular disease
  • COVID-19

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

17 pages, 3410 KiB  
Article
Serum Soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 (sLOX-1) Is Associated with Atherosclerosis Severity in Coronary Artery Disease
by Katharine A. Kott, Elijah Genetzakis, Michael P. Gray, Peter Hansen, Helen M. McGuire, Jean Y. Yang, Stuart M. Grieve, Stephen T. Vernon and Gemma A. Figtree
Biomolecules 2023, 13(8), 1187; https://doi.org/10.3390/biom13081187 - 29 Jul 2023
Viewed by 1013
Abstract
Risk-factor-based scoring systems for atherosclerotic coronary artery disease (CAD) remain concerningly inaccurate at the level of the individual and would benefit from the addition of biomarkers that correlate with atherosclerosis burden directly. We hypothesized that serum soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) [...] Read more.
Risk-factor-based scoring systems for atherosclerotic coronary artery disease (CAD) remain concerningly inaccurate at the level of the individual and would benefit from the addition of biomarkers that correlate with atherosclerosis burden directly. We hypothesized that serum soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) would be independently associated with CAD and investigated this in the BioHEART study using 968 participants with CT coronary angiograms, which were scored for disease burden in the form of coronary artery calcium scores (CACS), Gensini scores, and a semi-quantitative soft-plaque score (SPS). Serum sLOX-1 was assessed by ELISA and was incorporated into regression models for disease severity and incidence. We demonstrate that sLOX-1 is associated with an improvement in the prediction of CAD severity when scored by Gensini or SPS, but not CACS. sLOX-1 also significantly improved the prediction of the incidence of obstructive CAD, defined as stenosis in any vessel >75%. The predictive value of sLOX-1 was significantly greater in the subgroup of patients who did not have any of the standard modifiable cardiovascular risk factors (SMuRFs). sLOX-1 is associated with CAD severity and is the first biomarker shown to have utility for risk prediction in the SMuRFless population. Full article
(This article belongs to the Special Issue Cardiovascular Diseases and Biomarkers)
►▼ Show Figures

Figure 1

13 pages, 922 KiB  
Article
FK506-Binding Protein like (FKBPL) Has an Important Role in Heart Failure with Preserved Ejection Fraction Pathogenesis with Potential Diagnostic Utility
by Michael Chhor, Hao Chen, Djurdja Jerotić, Milorad Tešić, Valentina N. Nikolić, Milan Pavlović, Rada M. Vučić, Benjamin Rayner, Chris J. Watson, Mark Ledwidge, Kenneth McDonald, Tracy Robson, Kristine C. McGrath and Lana McClements
Biomolecules 2023, 13(2), 395; https://doi.org/10.3390/biom13020395 - 18 Feb 2023
Cited by 2 | Viewed by 2172
Abstract
Heart failure (HF) is the leading cause of hospitalisations worldwide, with only 35% of patients surviving the first 5 years after diagnosis. The pathogenesis of HF with preserved ejection fraction (HFpEF) is still unclear, impeding the implementation of effective treatments. FK506-binding protein like [...] Read more.
Heart failure (HF) is the leading cause of hospitalisations worldwide, with only 35% of patients surviving the first 5 years after diagnosis. The pathogenesis of HF with preserved ejection fraction (HFpEF) is still unclear, impeding the implementation of effective treatments. FK506-binding protein like (FKBPL) and its therapeutic peptide mimetic, AD-01, are critical mediators of angiogenesis and inflammation. Thus, in this study, we investigated—for the first time—FKBPL’s role in the pathogenesis and as a biomarker of HFpEF. In vitro models of cardiac hypertrophy following exposure to a hypertensive stimulus, angiotensin-II (Ang-II, 100 nM), and/or AD-01 (100 nM), for 24 and 48 h were employed as well as human plasma samples from people with different forms of HFpEF and controls. Whilst the FKBPL peptide mimetic, AD-01, induced cardiomyocyte hypertrophy in a similar manner to Ang-II (p < 0.0001), when AD-01 and Ang-II were combined together, this process was abrogated (p < 0.01–0.0001). This mechanism appears to involve a negative feedback loop related to FKBPL (p < 0.05). In human plasma samples, FKBPL concentration was increased in HFpEF compared to controls (p < 0.01); however, similar to NT-proBNP and Gal-3, it was unable to stratify between different forms of HFpEF: acute HFpEF, chronic HFpEF and hypertrophic cardiomyopathy (HCM). FKBPL may be explored for its biomarker and therapeutic target potential in HFpEF. Full article
(This article belongs to the Special Issue Cardiovascular Diseases and Biomarkers)
►▼ Show Figures

Graphical abstract

Other

Jump to: Research

14 pages, 1281 KiB  
Systematic Review
Diagnostic and Prognostic Role of CD93 in Cardiovascular Disease: A Systematic Review
by Federica Piani, Giovanni Tossetta, Gabriel Cara-Fuentes, Davide Agnoletti, Daniela Marzioni and Claudio Borghi
Biomolecules 2023, 13(6), 910; https://doi.org/10.3390/biom13060910 - 30 May 2023
Cited by 6 | Viewed by 1712
Abstract
Introduction. Cluster of Differentiation (CD) 93 (also known as complement protein 1 q subcomponent receptor C1qR1 or C1qRp) is a transmembrane glycoprotein that can also be present in a soluble (sCD93) form. Recent studies have investigated the role of this protein in cardiovascular [...] Read more.
Introduction. Cluster of Differentiation (CD) 93 (also known as complement protein 1 q subcomponent receptor C1qR1 or C1qRp) is a transmembrane glycoprotein that can also be present in a soluble (sCD93) form. Recent studies have investigated the role of this protein in cardiovascular disease (CVD). The present systematic review aims to assess the associations between CD93 and cardiovascular (CV) risk factors and disease at both the proteomic and genomic levels. Methods. We conducted systematic searches in the PubMed, EMBASE, and Web of Science databases to identify all human studies since inception to February 2023 that investigated the role of CD93 in CV risk factors, CVD, and CV-associated outcomes. The data collection and analysis have been independently conducted by two reviewers. The search terms included: cardiovascular, heart failure, acute stroke, myocardial infarction, stroke, peripheral artery disease, cardiovascular death, MACE, hypertension, metabolic syndrome, hyperuricemia, diabetes, cd93, c1qr, C1qR1, complement protein 1 q subcomponent receptor. Results. A total of 182 references were identified, and 15 studies investigating the associations between CD93 protein levels or CD93 genetic polymorphisms and the development or prevalence of CV risk factors (i.e., hypertension, dyslipidemia, and obesity) and CVD (i.e., heart failure, coronary artery disease, and ischemic stroke) were included. Although promising, the quality and dimension of the analyzed studies do not allow for a definitive answer to the question of whether CD93 may hold diagnostic and prognostic value in CVD. Full article
(This article belongs to the Special Issue Cardiovascular Diseases and Biomarkers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop